Biotech Sector Performance in April: Gilead Sciences Rising
Not pretty, but then, you already know that. Rising off the mid-month low is something to be happy about, I guess.
Here's where we stand year to date:
Must Read: Endocyte Falls on Ovarian Cancer Drug Blowup
I've noted previously the correlation between the declines in Gilead Sciences (GILD - Get Report) and the broader biotech sector. April broke that trend, which is an encouraging sign that investors are perhaps starting to differentiate between quality stocks and over-valued garbage.
The April performance of big-cap biotech stocks: